TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 34nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 60nMAssay Description:Inhibition of human PRMT5 co-complexed with MEP50 in absence of MTA using biotin labelled histone H4 peptide (1 to15) as substrate assessed as inhibi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 62nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 62nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 79nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 101nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 110nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 118nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 320nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 322nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetMethylosome protein 50/Protein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 410nMAssay Description:Inhibition of PRMT5/MEP50 (unknown origin) using Histone H2A as substrateMore data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 510nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 569nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 653nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 670nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 710nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 710nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 826nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 834nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 910nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: >1.00E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.05E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.06E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.21E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in human HCT-116 cells expressing wild type MTAP assessed as inhibition of PRMT5- mediated SDMA modifi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.29E+3nMAssay Description:Inhibition of human PRMT5 co-complexed with MEP50 in absence of MTA using biotin labelled histone H4 peptide (1 to15) as substrate assessed as inhibi...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.47E+3nMAssay Description:Inhibition of PRMT5 methyltransferase activity in MTAP knockout human HCT-116 cells assessed as inhibition of PRMT5- mediated SDMA modification level...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5(Homo sapiens (Human))
Mirati Therapeutics
Curated by ChEMBL
Mirati Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.85E+3nMAssay Description:Inhibition of MTA-bound human PRMT5 co-complexed with MEP50 using biotin labelled histone H4 peptide (1 to 15) as substrate assessed as inhibition of...More data for this Ligand-Target Pair